ACL
Australian Clinical Labs Limited
1 day chart
About ACL
Australian Clinical Labs Limited (ACL) is a leading private provider of pathology services in Australia. Our 75 NATA-accredited laboratories perform over 12 million episodes each year for clinicians and patients within our communities.
Buy Australian shares starting with ACL. Invest today with a CHESS-sponsored investing platform!
Market Capitalisation
$543M
Price-earnings ratio
15.07
Dividend yield
5.02%
High today
$2.79
Low today
$2.68
Open price
$2.70
52-week high
$3.87
52-week low
$2.69
Announcements
ACL FAQs
Can I buy ACL shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?
Yes, the Stake platform allows you to buy ACL shares and over 8,000 stocks and ETFs across the ASX and Wall St.
How much is one share of Australian Clinical Labs Limited?
One share of Australian Clinical Labs Limited is valued at $2.74.
What is the ticker symbol for Australian Clinical Labs Limited?
The ticker symbol for Australian Clinical Labs Limited is ACL.
How do I buy ACL shares in Australia?
To buy ACL stocks in Australia you'll need to open an account with an investing platform like Stake.
To do so follow these steps:
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake AUS
- Deposit directly into your Stake wallet and you're ready to invest in ACL
What is the 52-week high for Australian Clinical Labs Limited stock?
The Australian Clinical Labs Limited 52-week high stock price is $3.87.
What is the 52-week low for Australian Clinical Labs Limited stock?
The Australian Clinical Labs Limited 52-week low stock price is $2.69.
What is the market capitalisation of Australian Clinical Labs Limited ACL?
As of 04/10/2023 Australian Clinical Labs Limited has a market cap of $543M.
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.